Common pitfalls in managing regulatory compliance for combination products

Navigating the complex landscape of combination product regulation requires a strategic approach that bridges the gap between drug and device authorities. Companies must carefully align their submission strategies to avoid costly delays while ensuring patient safety is never compromised by procedural oversights.

The Fragmented Regulatory Landscape

Combination products represent a unique challenge because they sit at the intersection of multiple regulatory domains. Unlike single-mechanism drugs or standalone medical devices, these products often require dual oversight from agencies like the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH), or their global equivalents. The primary pitfall here is attempting to submit the product as a single entity without clearly delineating the responsibilities of each component. If a manufacturer fails to correctly classify the product's primary mode of action or intended use, they risk triggering a jurisdictional dispute that can stall clinical trials and market access for months. This misalignment often stems from a lack of clear internal definitions regarding what constitutes the "drug" portion versus the "device" portion of the final assembly.

Misalignment of Submission Strategies

One of the most common operational errors occurs during the planning phase of regulatory submissions. Teams frequently attempt to use a single package insert or labeling strategy for both the drug and device components, assuming that a unified approach will streamline the review process. In reality, regulators often require distinct labeling elements for each classification, including specific warnings, contraindications, and usage instructions tailored to the specific regulatory pathway. When companies do not prepare separate but harmonized labeling documents, reviewers may return the submission with "deficiencies" or request additional information (RI), necessitating costly resubmissions. Furthermore, the timeline for review differs significantly between drug and device pathways; ignoring these discrepancies can lead to scheduling conflicts where the device clearance is delayed while the drug approval is pending, or vice versa, creating an unstable regulatory status for the entire product.

Confusing Indications with Mechanisms

Defining the Primary Mode of Action

A critical source of confusion lies in defining the product's primary mode of action and intended use, which dictates the applicable regulatory guidance. Many organizations struggle to distinguish between products where the active pharmaceutical ingredient (API) is responsible for the therapeutic effect versus those where the device's physical properties drive the outcome. For example, in a drug-eluting stent, the drug coating is the primary mode of action, yet the device is essential for delivery. If a company misclassifies a product based on an unclear understanding of its mechanism, they may inadvertently submit under the wrong guidance, leading to incomplete data requirements or missing safety assessments. This ambiguity often arises from insufficient cross-functional collaboration between clinical, medical, and regulatory teams early in the development lifecycle.

To ensure clarity, organizations must rigorously evaluate their product against specific criteria. Consider the following checklist to determine the primary classification:

  • Is the drug component essential for the product's intended use, or can the device function independently?
  • Does the device component perform the primary function, while the drug merely modifies the outcome?
  • Would the product fail to achieve its intended use without the drug component?
  • Is the device used for a specific medical purpose that the drug alone cannot provide?
  • Does the FDA guidance specifically address the combination product based on the drug's dominance?

Answering these questions systematically helps prevent jurisdictional disputes before a submission is even drafted.

Global Regulatory Harmonization Challenges

While regional agencies are increasingly moving toward harmonization, significant differences remain in how they evaluate combination products, particularly regarding data generation and labeling formats. A submission accepted in one region may be rejected in another due to divergent requirements for clinical evidence or specific labeling layouts. Companies often underestimate the effort required to localize their regulatory strategy for multiple territories simultaneously. Without a robust global regulatory strategy that accounts for these nuances, organizations risk creating parallel development streams that are inconsistent with each other, leading to fragmented market access and inefficient resource allocation. It is vital to engage with regulatory affairs specialists in each target jurisdiction early to identify specific divergences.

Overlooking Post-Market Surveillance Requirements

Finally, many organizations neglect the post-market obligations that accompany combination product approvals. Once a product is approved, manufacturers face ongoing responsibilities such as adverse event reporting, periodic safety update submissions, and device registries that differ depending on the classification of the device component. Failure to maintain accurate, up-to-date documentation for these post-market requirements can result in regulatory notices, enforcement actions, or even product recalls. It is crucial to integrate post-market compliance planning into the pre-market development phase, ensuring that all data collection systems and reporting mechanisms are aligned with both drug and device regulations from day one. By proactively addressing these pitfalls, companies can ensure smoother regulatory navigation and faster time to market.

Related reading